SURVYR

ABSI

Absci Corporation
$11.88
+$1.31 (12.39%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-50%+4%+59%+113%+168%Oct 2025Oct 2026Apr 202652w high $12.0552w low $2.24
ABSISPY
Wall St. Highest PT $20.00 (+68.4%) Wall St. Avg PT $14.90 (+25.4%)
$2$7$11$16$21POC $3Hi $20Avg $15
Underwater Drawdown %Max DD -48.9%Current 0.0%
0.0%-48.9%
Relative Strength vs SPY+150.1% vs SPYOutperforming
+173%0%-173%
1W
+$1.84 (18.33%)
1M
+$2.39 (25.18%)
3M
+$4.98 (72.17%)
6M
+$7.17 (152.23%)
YTD
+$8.39 (240.40%)
1Y
+$7.48 (170.00%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
10 analysts · mean score 1.36
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$11.88
Average target$14.90
+$3.02 (+25.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$10.00
Median$14.90
High$20.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.7B
P/E (next 12 months, estimated)-14.9
52-week range$2.24 – $12.05
Revenue growth (latest quarter vs a year ago)-46.4%
Dividend yieldNo dividend
Analyst consensusStrong Buy (10)
Average analyst price target$14.90 (+25%)

What they do

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ABSI yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 5 of 589 · 12-month momentum 204.4%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ABSI earningsNext report in 15 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.20
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.21est -$0.20−6.4%Below estimates
May 7, 2026-$0.19est -$0.20+4.6%Above estimates
Mar 24, 2026-$0.23est -$0.17−32.5%Below estimates
Nov 12, 2025-$0.20est -$0.21+2.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:46:33 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.250.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally
TIKR · 9h ago
Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:46:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026